-+ 0.00%
-+ 0.00%
-+ 0.00%

Purple Biotech Presents New Data Regarding Its Tri-Specific Antibody Platform, CAPTN-3

Benzinga·10/25/2024 11:23:42
Listen to the news

Investigational New Drug (IND) enabling work is aimed to reach first in human clinical studies with our lead candidate IM1240 potentially by 2026. 

The platform's lead compound IM1240 (aCD3xa5T4xaNKG2A) targets 5T4, a TAA expressed in a variety of solid tumors and which is correlated with advanced disease, increased invasiveness, and poor clinical outcome.